1. Introduction {#s0005}
===============

Infectious diseases that affect the central nervous system (CNS) have been increasing in incidence over the last several years ([@b0490]). Possible factors that contribute to the increased incidence and emergence of new pathogens that cause neuroinfections include globalization, climate change, and the increased contact of humans with wild animals ([@b0190], [@b0445]). Several pathogenic organisms, including viruses, bacteria, fungi, and parasites, can present considerable neurotropism for the CNS, generating neuroinflammation and neurodegeneration ([@b0085]). Neuroinfectious diseases create an inflammatory microenvironment that may have negative consequences on the quality of life and social activities of infected individuals, including cognitive dysfunction, behavioral changes, depression, seizures, and physical impairments. Despite these harmful outcomes, neurological symptoms verified in infectious diseases that affect CNS are usually neglected ([@b0055]).

The endothelial blood--brain barrier (BBB) is the primary regulation point for the entrance of circulating immune cells and pathogens within the CNS ([@b0185]). The BBB is formed by tight junctions between endothelial cells, pericytes, and astrocytes ([@b0415]). In addition to the BBB, other cellular and acellular barriers that separate the brain from the periphery include the arachnoid barrier and the blood-cerebrospinal fluid barrier (BCSFB). All these specific and protective segments explain the varying immunological interactions between the CNS and the peripheral nervous system (PNS) ([@b0185], [@b0225]).

The blood--brain barrier, together with an absence of lymphatic vessels, constituted an anatomical peculiarity that characterized the CNS as an immune-privileged site, where undesired inflammatory processes are inhibited ([@b0100]). Functional initial afferent lymphatic vessels in the outermost layer of the meninges in the CNS were described in 2015. This paradigm displaced the immune privilege hypothesis ([@b0425]). Subsequently, the presence of lymphatic vasculature in the CNS gave rise to the immunomodulatory parenchymal competence concept within the CNS ([@b0225]).

Blood-borne pathogens can cross the BBB to reach the CNS, generating a disruptive inflammatory scenario. They penetrate the barrier via transcellular or paracellular pathways, or through infected leukocytes---the "Trojan horse" method. Some pathogens can also circumvent the barriers and access the CNS through peripheral nerves by axonal transport ([@b0180]). Finally, pathogens may benefit from immunomodulatory competence that protects them from immune cell activity. This phenomenon impairs complete pathogenic clearance, thereby permitting establishment of latent infections ([@b0225]).

The immune system establishes a relationship with the CNS to maintain homeostasis. The CNS presents limited degrees of innate and adaptive immunity; however, in the CNS parenchyma, microglia are the primary resident immune cells; these cells originate early in embryonic development ([@b0275]). They are immediately activated after infection, thereby promoting neuroinflammation. Excessive inflammation stimulates cell death and excitotoxicity, leading to dangerous consequences such as neurodegeneration ([@b0225], [@b0465]).

Excitotoxicity can be caused by excessive or prolonged extracellular accumulation of excitatory neurotransmitters, such as ATP and glutamate in particular ([@b0130], [@b0525], [@b0660]). Inflammatory events increase glutamate release by glial cells, inducing over-activation of glutamatergic receptors such as the N-methyl-D-aspartate (NMDA) receptor ([@b0300], [@b0525]). The over-activation of these receptors abnormally increases intracellular Ca^+2^ concentrations, triggering the production of reactive oxygen and nitrogen species and reducing the energy metabolism of cells ([@b0525]). The production of free radicals and the decreased production of ATP affects the activity of membrane ion pumps, such as the Na^+^,K^+^-ATPase, which is crucial for maintaining the Na^+^ gradient for glutamate uptake ([@b0525]). These events contribute to potentiation of extracellular glutamate accumulation and excitotoxicity. In addition, the loss of ionic homeostasis induces cell damage, death, and degeneration ([@b0300], [@b0525])

In addition to glial cells, circulating immune cells can be recruited to brain parenchyma to control the infection when the endothelial barriers are impaired ([@b0540]). This migration is a cell-dependent and barrier-dependent process that is usually mediated through blood vessels localized under the arachnoid barrier ([@b0085]). These neuroinflammatory and neurodegenerative processes, and also the immune response to pathogens, involve several signaling pathways, including purinergic signaling ([@b0205], [@b0590], [@b0585]).

Purinergic signaling is an evolutionarily conserved cell communication mechanism mediated by extracellular nucleotides and nucleosides ([@b0075]). In 1929, the first study related to purinergic signaling was published presenting adenosine (ADO) as a molecule functionally similar to adenylic acid in the cardiovascular system ([@b0210]). In the early 1970s, a seminal study described ATP and related compounds as signaling molecules in the nervous system of the gut ([@b0070]). Shortly thereafter, the purinergic hypothesis was proposed ([@b0065]). The importance of nucleotides for cell communication in various organ systems is currently well defined: Purinergic signaling modulates neurotransmission and neuroinflammation that are involved in behavioral processes and both genetic or acquired neuropathological conditions ([@b0060]).

The purinergic receptors are composed of two subgroups that are expressed throughout the mammalian body: P2 receptors for tri- and diphosphonucleotides such as ATP, ADP, UTP, UDP, and UDP-glucose; and P1 receptors for ADO. The P1 receptors are divided into four subtypes: A~1~, A~2A~, A~2B~, and A~3~. They are metabotropic G protein-coupled receptors linked to activation (A~2A~ and A~2B~) or inhibition (A~1~ and A~3~) of adenylyl cyclase ([@b0270], [@b0555]). The P2 receptors are divided into two major subclasses: P2X and P2Y. The P2Y family is also composed of G protein-coupled receptors. Currently, there are eight distinct P2Y subtypes cloned and characterized in mammals: P2Y~1~, P2Y~2~, P2Y~4~, P2Y~6~, P2Y~11~, P2Y~12~, P2~13~, and P2Y~14~ ([@b0355], [@b0555]). Seven ionotropic receptors form the P2X family (P2X1--P2X7). Among the P2X receptors, the P2X7 receptor is the most involved in inflammatory processes. It plays a crucial role in neuromodulation and neuroinflammation in CNS, together with other purinergic receptors, especially P2X4, P2Y~6~, P2Y~12~, and A~2A~ ([@b0060], [@b0345])~.~

The association between P2X7 receptors stimulation and IL-1β maturation and release was first identified in microglial cells ([@b0255]). Currently, the P2X7 receptor is well characterized as the second signal for inflammasome activation that culminates in the cleavage and subsequent release of pro-IL-1β through activation of caspase-1 ([@b0250]). The P2X7 receptor induces activation of several microbicidal mechanisms during pathogen infections ([@b0590], [@b0585]), and this receptor is also involved in various brain pathologies, including, among others, Alzheimer's disease, sepsis-associated encephalopathy, multiple sclerosis, crucial to neuropathic pain, and behavioral conditions such as bipolar disorder and depression ([@b0205], [@b0430], [@b0530], [@b0590], [@b0605]). The P2Y~12~ receptor mediates the initial microglial migration to injured regions in the CNS ([@b0305]), while P2Y~6~ activation by UDP stimulates microglial phagocytosis of dying cells ([@b0395]). P2X4 receptor expression in spinal microglia is crucial to pain hypersensitivity after nerve injury ([@b0645]). Finally, the A~2A~ receptor in neurons promotes neurodegeneration, while its expression in microglia and astrocytes promotes neuroprotection ([@b0160]).

The metabolism of released nucleotides is controlled by ectoenzymes named ectonucleotidases. Of these, the most important ones in the neuroimmune context are E-NTPDase1/CD39, NTPDase2/CD39L1, and NTPDase3/CD39L3 that catalyze the hydrolysis of ATP and ADP to AMP and the ecto-5′-nucleotidase/CD73 that catalyzes the hydrolysis of AMP to adenosine ([Table 1](#t0005){ref-type="table"} ). The nucleoside adenosine can be deaminated to inosine by adenosine deaminase (ADA) ([@b0035], [@b0565]). After cortical stab injury, increased hydrolysis of all three adenine nucleotides was specifically observed in the injured cortex. These effects correlate with the upregulation of ectonucleotidases, with CD73 being most highly expressed in astrocytes, whereas CD39 was most highly expressed in microglial cells ([@b0500]). CD39 also modulates the migratory activity of microglial cells, as this enzyme controls ATP and adenosine levels, both of which are fundamental molecules to microglial migration ([@b0230]). These ectonucleotidases are involved in several neuropathologies, including, but not limited to epilepsy, Alzheimer's, and Parkinson's disease ([@b0035], [@b0140], [@b0405], [@b0475]).Table 1Expression and functional roles of purinergic receptors, E-NTPDases, and ecto-5′-nucleotidase/CD73 in CNS cells during brain infections.CNS cell typeComponents of purinergic signalingExpression profile and/or involvement in functional responses in neuroinfectionsReferencesMicrogliaP2 receptors: P2X4; P2X7; P2Y4; P2Y~6~; P2Y~12~; P2Y~13~HIV: P2X7 induces the production ROS, NO, IL-1β, and TNF-α, resulting in microglial loss.[@b0110]HSV-1: P2Y12 increase phagocytic function.[@b0240]SAE: P2X7 inhibition/deletion decreases microglial activation.[@b0675]P1 receptors: A~1~; A~2A~; A~2B~; A~3~TMEV: A~2A~ mediates cannabidiol-induced decreases in microglial activation.[@b0470]NTPDase1/CD39; NTPDase2/CD39L1; CD73HSV-1: Increases CD39 activity.[@b0240]AstrocytesP2 receptors: P2X4; P2X7; P2Y1; P2Y~2~; P2Y~4~; P2Y~6~ P2Y~12~; P2Y~13~; P2Y~14~HIV: P2Y4 induces cytokine and chemokine release.[@b0720]HIV: P2X7 is upregulated, inducing neuronal death.[@b0635]P1 receptors: A~1~; A~2A~; A~2B~; A~3~Undefined roles in CNS infections.NTPDase1/CD39; NTPDase2/CD39L1; CD73*T. gondii*: CD73 promotes tachyzoite-to-bradyzoite differentiation and parasite persistence in the CNS.[@b0450]NeuronsP2 receptors: P2X2; P2X4; P2X7[\*](#tblfn1){ref-type="table-fn"}; P2Y~1~; P2Y~2~; P2Y~4~; P2Y~12~; P2Y~13~SAE: P2X7 deletion decreases neurodegeneration.[@b0675]HIV: astrocytic P2Y4 induces apoptosis and neuronal death.[@b0720]HIV: astrocytic P2X7 contributes to neuronal death[@b0635]P1 receptors: A~1~; A~2A~; A~2B~; A~3~HIV: A1 has neuroprotective effects.[@b0535]NTPDase3/CD39L3; CD73Undefined roles in CNS infections.[^3][^4]

Considering the involvement of purinergic receptors and ectonucleotidases in neuroinflammatory and host-pathogen interaction mechanisms, in this review, we discuss advances in the understanding of the role of purinergic signaling in the balance of protective and deleterious inflammatory responses in infectious diseases of CNS.

2. Purinergic signaling in neuroinfectious diseases {#s0010}
===================================================

2.1. Viral infections {#s0015}
---------------------

The central nervous system is a major target for viruses that can reach the brain parenchyma and infect neuronal and glial cells. Neuroinfections result in severe neurological complications, including neuroinflammation, encephalitis, neurodegeneration, behavioral changes, and others ([@b0465]). ATP is released from infected cells in the extracellular milieu where it acts as a danger signal activating surrounding cells that respond by producing inflammatory mediators to control the infection ([@b0590]). Nevertheless, these responses can exacerbate and progress to deleterious consequences. In recent years, several studies have suggested that purinergic signaling is crucial to the outcome of viral infections, influencing both clearance and persistence of the virus in the central nervous system ([@b0245]).

The acquired immunodeficiency syndrome (AIDS), caused by the human immunodeficiency virus (HIV-1), induces neurodegeneration affecting cognitive, motor and, behavioral abilities in almost half of the patients, even with the use of combination antiretroviral therapy ([@b0310]). HIV-associated dementia is the worst of the HIV-associated neurocognitive disorders. This severe neurological complication is usually found in patients with late-stage AIDS, although it could also be detected early in the development of the disease ([@b0310], [@b0495]). The HIV transactivator of transcription (Tat) protein and the envelope glycoprotein gp120 act as neurotoxins that stimulate secretion of cytokines such as TNF-α, leading to a dangerous scenario characterized by infected-leukocyte infiltration, inflammation, and neuronal loss ([@b0560], [@b0570]). These processes promote neurocognitive dysfunction that eventually evolves into HIV-dementia.

A typical feature of HIV neuroinfection is neuronal loss ([@b0615]). Tewari and colleagues showed that Tat protein upregulates P2X7 receptor astrocytic expression that results in neuronal death. P2X7 receptor also mediates Tat-induced CCL2 astrocytic release. This chemokine facilitates the infiltration of leukocytes, thereby promoting a pro-inflammatory environment ([@b0635]). Tat also induces the overexpression of P2Y~4~ receptor in astrocytes. This purinergic receptor induces cytokine and chemokine release that contributes to apoptosis and neuronal death ([@b0720]). Furthermore, Tat protein induces monocyte/macrophage infiltration in the CNS, thereby contributing to HIV-dementia development, as this condition is associated with immune cell infiltration ([@b0545]). In this context, A~2A~ receptor activation reduces Tat-induced TNF-α production in HIV-infected monocytes. In addition, A~1~ receptor stimulation has protective effects against HIV-1 Tat-induced toxicity in primary cultures of rat cerebellar granule neurons and in rat pheochromocytoma (PC12) cells ([@b0535]) ([Table 1](#t0005){ref-type="table"}). These findings suggest that adenosine may have a protective role, attenuating the production of pro-inflammatory cytokines by monocytic cells that migrate to CNS ([@b0265]).

The gp120 protein also upregulates the P2X7 receptor in microglial cells. This receptor, in turn, induces the expression of inflammatory mediators such as ROS, NO, IL-1β, and TNF-α, resulting in microglial loss ([@b0110]). Gp120-induced cognitive impairment, including memory and learning deficits, can also occur through P2X7 receptor-dependent mechanisms ([@b0420]). Gp120 also triggers neuropathic pain in HIV patients, a complication displayed in many HIV-neurological disorders ([@b0705]). This neurotoxin enhances P2Y~12~ receptor expression in glial cells of dorsal root ganglia, activating these cells. Once active, these glial cells increase their expression of pro-inflammatory cytokines such as TNF-α and IL-1β. These are essential cytokines for the development and preservation of thermal and mechanical pain, common features of neuropathic pain ([@b0620]). Taken together, these reports suggest that P2 receptors are deleterious, and P1 receptors are neuroprotective in HIV-dementia. Moreover, such findings support a possible role for ectonucleotidases in this disease, because these enzymes catalyze the hydrolysis of nucleotides to adenosine.

Theiler's murine encephalomyelitis virus (TMEV) infection in susceptible mice strains can persist and develop into a late chronic disease, the symptoms of which include demyelination of white matter, resulting in neurological damage. In humans, multiple sclerosis (MS) is also a demyelinating disease that affects the brain and spinal cord. These findings suggest that TMEV has similarities with multiple sclerosis, including inflammatory cell infiltration, axonal damage, and disruption of the blood--brain barrier ([@b0515]). In TMEV disease, the recruitment of leukocytes is a classic step in the development of neuroinflammation. The infection promoted by this cardiovascular virus can be limited by infiltrated leukocytes, including T cells whose activation can be modulated by microglia, preventing neurodegeneration, seizure episodes, and hippocampal injury ([@b0670]). The anti-inflammatory abilities of cannabidiol attenuate cytokine production and the expression of the vascular cell adhesion molecule-1 (VCAM-1), a pivotal protein in the process of migration of circulating immune cells. These protective effects are partially mediated by the A~2A~ receptor, because the antagonism of this receptor inhibited the beneficial effects of cannabidiol, including the diminished VCAM-1 expression ([@b0470]).

The herpes simplex virus type 1 (HSV-1) is responsible for more than half of viral encephalitides with clinical manifestations, including seizures, mental impairment, and acute fever ([@b0115]). HSV-1-infected neuronal cells release nucleotides such as ATP that activate and recruit microglia. Then, there is an increase of ectonucleotidase activities (i.e., CD39) to generate more ADP in the extracellular milieu. ADP activates P2Y~12~ receptors in microglia, increasing migration and phagocytic function to clear compromised neurons before cell membrane rupture. This mechanism reduces abnormal neuronal function that could culminate in HSV-1 encephalitis ([@b0240]). P2Y~12~ receptor is essential for microglial process extension and migration. The P2Y~12~ receptor triggers phosphatidylinositol 3-kinase (PI3K) and phospholipase C (PLC) pathway activation, which generate inositol 1,4,5-triphosphate (PIP3) inducing calcium release from intracellular stores ([@b0345], [@b0350]). The increase in intracellular Ca^+2^ concentrations is crucial for cytoskeletal reorganization and cell migration. After cell migration, P2Y~12~ receptor downregulation contributes to microglial process retraction. Once microglia cells acquire their ameboid phagocytic phenotype, P2Y~4~ and P2Y~6~ receptors control phagocytosis and pinocytosis in these cells, respectively (reviewed in [@b0345]).

Zika virus (ZIKV) is an arbovirus from the Flaviviridae family transmitted mainly by mosquitoes from the *Aedes* genus, including *Aedes aegypti* or *Aedes africanus*. The relationship between ZIKV infection and fetal congenital malformation was first described in Brazil in 2015, when an outbreak of this arbovirus caused severe vertical infection in developing fetuses causing microcephaly and abnormalities in the brain and eyes. In adults, the virus causes meningoencephalitis and Guillain-Barré syndrome, an autoimmune disease that affects the nervous system ([@b0410]). The P2X7 receptor appears to be involved in the control of flavivirus as seen in human monocytes infected by dengue virus (DV), a virus closely related to ZIKV. Activation of this receptor reduced viral load in infected cells, mediated by higher levels of ROS and NO production ([@b0150]). ZIKV infection activates NLRP3 inflammasome activation and IL-1β secretion ([@b0680]). These findings suggest that the P2X7 receptor may possibly be involved in the pathophysiology of Zika virus infection, and may represent a potential therapeutic target.

The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) thought to be the causative agent of pandemic coronavirus disease 2019 (COVID-19) ([@b0370]). Patients with more severe outcomes often present with acute respiratory distress syndrome (ARDS). In addition to affecting the respiratory tract, SARS-CoV-2 may present a neuroinvasive profile, and can reach the central nervous system as do other coronaviruses ([@b0690]), possibly through lymphatic vessels ([@b0040]). The ability of this virus to induce neurological symptoms such as headache, acute cerebrovascular diseases, and disturbed consciousness in patients with severe respiratory distress has already been reported ([@b0455]). Furthermore, SARS-CoV-2 may cause patients to become more susceptible to neuroleptic malignant syndrome (NMS), meningoencephalitis, hypogeusia, hyposmia, and even to develop autoimmune disorders that affect neuronal cells, including Guillain-Barré syndrome, regardless of the respiratory condition ([@b0135], [@b0215], [@b0385], [@b0655]).

The clinical and pathological characteristics presented by SARS-CoV-2 patients may be due to virally-induced cytokine storm, with the hyperinflammation scenario stimulating severe lung disease ([@b0370]). This pulmonary dysfunction can lead to ARDS, which shares various traits with severe pneumonia, the primary complication in hospitalized COVID-19-infected individuals ([@b0375]). Interestingly, ATP-P2X7 receptor signaling mediates LPS-induced ARDS/ALI (acute lung injury) ([@b0120], [@b0480]). Beyond lung epithelial cells, SARS-CoV-2 also presents tropism to macrophages; inhibition of macrophage might prevent coronavirus-related injuries ([@b0235]). Because the P2X7 receptor is strongly expressed on macrophages and microglia, inducing IL-1β, IL-18 and IL-6 secretion, and because these cells express angiotensin-converting enzyme 2 (ACE2; the receptor used by this virus to infect cells), a recent report introduced the idea that blockade of this purinergic receptor could be a potential target to suppress COVID-19 infection ([@b0665]). A recent study found that Anakinra, a human IL-1 receptor antagonist, improved outcomes and decreased mortality among patients with severe forms of COVID-19 ([@b0330]). Taken together, the data suggest that purinergic signaling may be possible involved in the neurological symptoms induced by SARS-CoV-2.

These reports provide evidence for an essential role of purinergic signaling in viral neuroinfectious. Nevertheless, the deleterious or beneficial outcomes depend on the virus species and virulence, as well as the particular purinergic receptor or ectonucleotidase involved in the disease neuropathology. Further studies are needed to better understand purinergic signaling in viral infections, especially in emerging viral infections that affect the central nervous system such as Zika and SARS-CoV-2.

2.2. Bacterial infections {#s0020}
-------------------------

Bacterial infections of the central nervous system are significant causes of morbidity and mortality. These infections are usually associated with encephalitis and meningitis, among the top ten infectious diseases causing death worldwide ([@b0435]). The most important pathogens that cause these conditions are S. pneumoniae followed by Streptococcus agalactiae, Neisseria meningiditis, Haemophilus influenzae, and Listeria monocytogenes ([@b0085], [@b0180]). Polymicrobial sepsis is also a severe medical condition that causes neurological symptoms.

High-grade bacteremia and BBB dysfunction are important predisposing factors permitting these pathogens to reach the brain. They invade the CNS through transcellular or paracellular penetration or by infiltrating infected leukocytes, inducing neuroinflammation, excitotoxicity, and neurodegeneration. Interestingly, purinergic signaling is involved in the modulation of these neuropathological mechanisms ([Table1](#t0005){ref-type="table"}) ([@b0180], [@b0600]).

Sepsis-associated encephalopathy (SAE) promotes brain dysfunction and is associated exacerbated systemic infection, cytokine release, and immune cell infiltration. In response to this intense inflammatory process, the BBB loses its integrity and protective functions ([@b0510]). The P2X7 receptor triggers brain endothelial dysfunction, contributing to SAE pathogenesis. The P2X7 receptor is co-localized with the adhesion molecule ICAM-1, and both of these proteins are highly expressed in cerebral vessels 4 h after sepsis induction by CLP. Furthermore, leukocyte adhesion, microglial activation, and ICAM-1 expression were decreased when P2X7 signaling was blocked by shRNA or a specific antagonist (A438079). BBB integrity was preserved in P2X7^−/−^ septic mice, demonstrating a critical role for this receptor in SAE ([@b0675]). In the same line of evidence, P2X7^−/−^ septic mice showed decreased ROS and RNS production and increased SOD and CAT activities in cerebral cortex and hippocampus when compared to WT septic animals ([@b0580]). P2X7 receptor genetic deletion also decreased IL-1β and IL-6 production in both brain structures. Furthermore, CD39^−/−^ mice showed increased cytokine production in the brain parenchyma after induction of sepsis, in comparison to WT mice. P2X7 receptor pharmacological blockade inhibited these effects, suggesting that ATP-P2X7 signaling is critical for neuroinflammation in SAE ([@b0580]). In accordance with these findings, Zhang et al. recently showed that ATP concentrations increase in the cerebrospinal fluid of septic mice. Considering that ATP release can occur via pannexin-1 channels, the authors found that blockade of this channel improved cognitive behavior and decreased cytokine production (i.e., IL-1β, IL-6, and TNF-α) in the hippocampus of septic mice ([@b0715]).

Pneumococcal infections can spread by aerosol and promote asymptomatic colonization of the nasal cavity. Once inside the nasal cavity, these bacteria spread to other organs, including the brain, by reaching the bloodstream and crossing the BBB, causing meningitis ([@b0315]). Some experimental meningitis models have been used to explain the pathogenesis of this disease. [@b0725] found that the purinergic signaling could be involved in meningitis. During pneumococcal meningitis, P2 receptor antagonism using suramin and BBG did not change the disease course, despite inhibition of IL-1β and IL-6 secretion in murine bone marrow-derived macrophage (BMDM) challenged by *S. pneumoniae*. The authors also showed that cerebral P2 receptor expression (P2X1, P2X4, P2X7, P2Y~4~, P2Y~12~ and P2Y~14~) was downregulated and that cerebrospinal fluid ATP concentration decreased in this meningitis model ([@b0725]). However, when human THP-1 cells were exposed to the same pathogen, the authors detected increased ATP levels in the supernatants. Furthermore, pretreatment with a P2X7 antagonist, oxidized ATP (ox-ATP), resulted in reduced IL-1β secretion and attenuated activation of caspase-1 and cathepsin B ([@b0320]). *In vivo* and *in vitro* analysis demonstrated that, even using other pathogens such as S. aureus and  *Escherichia* coli, ATP was released from host cells. This nucleotide protected against bacterial infections that cause meningitis via the P2X7 receptor and NLRP3 inflammasome activation, cytokine, and chemokine secretion, and by promoting neutrophil recruitment ([@b0695]).

Several studies reported that other bacteria could trigger the purinergic cascade to promote cerebral inflammation. Silver catfish infected with *S. agalactiae* showed increased brain levels of ATP and adenosine; in this model, IL-1, IL-6, and IL-7 levels increased as well ([@b0625]). Birds infected with *E. coli* presented enhanced ectonucleotidase activities in the cerebral cortex, possibly increasing adenosine formation ([@b0175]). Increased adenosine levels could be associated with anti-inflammatory and neuroprotective effects. Neuronal cells, astrocytes, microglia, and pericytes are regulated by adenosine. This molecule, which can be generated by CD73, regulates BBB permeability, neural transmission, and glial cell immune function during stress or injury ([@b0080]).

An *in vitro* model that mimics BBB was used to show that *H. influenzae* was able to penetrate endothelial cells, causing an increase in adenosine concentration; furthermore, when A~2A~ and A~2B~ receptors were inhibited, BBB integrity was maintained, suggesting that BBB permeability is modulated by these receptors ([@b0095]).

These reports provide evidence that purinergic signaling has an essential role in bacterial infections that cause neurological disorders. In general, ATP-P2 signaling has pro-inflammatory effects. Inhibition of these pathways or adenosine generation improves disease outcomes, decreasing the degree of inflammatory processes, and improving cognitive dysfunction ([Fig. 1](#f0005){ref-type="fig"} ). Nevertheless, further studies are needed to elucidate the peculiarities of purinergic signaling in each specific infection.Fig. 1. Schematic representation of purinergic signaling modulation in infectious diseases that affects the CNS. (A) In human immunodeficiency virus (HIV-1), P2X7, P2Y~4~, and P2Y~12~ receptors are upregulated and show deleterious pro-inflammatory effects, while A~2A~ has anti-inflammatory activity; In Theiler's murine encephalomyelitis virus (TMEV), A~2A~ also has an anti-inflammatory protective effect; Herpes simplex virus type 1 (HSV-1) infection increases CD39 and ADP levels, boosting microglial P2Y~12~ receptor activation, which in turns increases the phagocytosis of damaged neurons. (B) Sepsis-associated encephalopathy increases ATP concentration and P2X7 receptor expression with deleterious pro-inflammatory effects, while CD39 is protective. Pneumococcal meningitis induces downregulation of cerebral P2X1, P2X4, P2X7, P2Y~4~, P2Y~12~, P2Y~14~, and ATP levels. *S. agalactiae* infection increases ATP, ADO, and ectonucleotidase activities. In *H. influenzae* infection, A~2A~ and A~2B~ show deleterious effects, inducing BBB impairment. (C) *C. neoformans* infection increases ATP levels in brain tissue. (D) In *T. gondii* infection, the P2X7 receptor has protective effects inducing parasite control, while CD73-generated adenosine contributes to parasite spread and persistence. Cerebral malaria upregulates cerebral expression levels of P2X1, P2Y~2~, P2Y~12~, and P2Y~13~; *T. evansi* acute infection boosts brain ectonucleotidases, increases ATP and ADP levels, and decreases adenosine brain concentrations. Chronic *T. evansi* increases adenosine brain levels.

2.3. Fungal infections {#s0025}
----------------------

The fungus *Cryptococcus neoformans* is the causative agent of cryptococcosis, a disease that can be especially dangerous to immunocompromised hosts, particularly HIV-positive patients. The infection starts with the inhalation of the fungus, followed by dissemination to other organs via the bloodstream. This pathogen exhibits strong tropism for the CNS, leading to a potentially fatal meningoencephalitis ([@b0550]). *C. neoformans* can infect cerebral microvascular endothelial cells from the BBB via a transcellular pathway ([@b0105]). In addition to this mechanism, the pathogen can access the CNS using infected leukocytes such as monocytes and neutrophils ([@b0390]).

Evidence supports the involvement of purinergic signaling in cryptococcosis. The ATP and ADP hydrolysis are reduced in lymphocytes from *C. neoformans*-infected rats, suggesting a reduction of ectonucleotidase activities. These results are possibly connected to the stimulation of a pro-inflammatory scenario with an increase in ATP levels and cytokine production (i.e., ﻿TNF-α and INF-γ) ([@b0020]). Indeed, the total ATP concentration increases in the serum and brain tissue during cryptococcosis ([@b0195]). Further studies are needed to elucidate the role of purines and purinergic receptors in the pathophysiology of cryptococcosis.

2.4. Parasitic infections {#s0030}
-------------------------

*Toxoplasma gondii* is an obligate intracellular protozoan parasite that causes toxoplasmosis. Although the immune response in healthy individuals controls *T. gondii* infection, this parasite can be harmful and potentially fatal to the fetus during pregnancy and to immunocompromised individuals ([@b0595]). During acute infection, tachyzoites (the most infectious form) spread throughout almost the entire intestine, lymph nodes, and visceral organs. *T. gondii* can also reach the CNS, where it persists, inducing neurological dysfunction. In the chronic phase, the parasite can transform into bradyzoites and form cysts containing numerous parasites. This fact allows the persistence of the parasite in immunomodulatory sites such as the CNS, inducing neurological and behavioral alterations ([@b0595], [@b0650]).

The P2X7 receptor plays a critical role in the immune response against *T. gondii.* This receptor induces parasitic control in macrophages ([@b0155]) and human intestinal epithelial cells ([@b0325]) by triggering the activation of microbicidal mechanisms such as ROS production, NLRP3 inflammasome activation, and IL1-β secretion. P2X7-deficient mice are more susceptible to acute and lethal infections caused by type I *T. gondii* (RH) via an impaired immune response ([@b0145]). In a model of chronic toxoplasmosis induced by a cystogenic nonvirulent type II *T. gondii* strain (ME-49), P2X7 receptor genetic deletion increased the number of cysts in the mice brain and caused mortality at 6 weeks post-infection, suggesting that this receptor is important for induction of resistance to cerebral toxoplasmosis. Indeed, these knockout mice showed reduced production IL-1β, IL-12, and ROS in the brain, favoring parasite spread in the CNS ([@b0485]).

In a murine model of congenital toxoplasmosis, investigators isolated telencephalic neuronal progenitor cells from mouse embryos and detected decreased ATP hydrolysis and increased expression of P2X7 receptors in these cells ([@b0045]). They also found increased expression of the A~2A~ receptor and decreased adenosine deaminase activity, suggesting accumulation of adenosine. Gene expression levels of IL-6, INF-γ, TNF-α, and IL-10 also increased in cells from infected mice. Nevertheless, the parasite load was not assessed in these settings. The authors also found that resveratrol prevented some of these effects. Although they did not investigate the mechanism of action of resveratrol, these results may be related to its antioxidant and anti-inflammatory activities ([@b0045]).

[@b0640] measured levels of purines in the brains of rats infected with two *T. gondii* strains (RH and ME-49). The levels of purines (ATP, ADP, AMP, adenosine, inosine, xanthine, and hypoxanthine) increased in the brains of rats infected with the RH strain at 4- and 6-days post-infection. By contrast, purine levels significantly decreased in the brains of rats infected with type II cystogenic *T. gondii* strain (ME-49) 60 days post-infection. ADA activity decreased 30 days post-infection but increased 60 days post-infection in the brains of rats infected with the ME-49 strain. Taken together, these data suggest that purine concentrations and ADA activity in the brain can vary during disease evolution, and may depend on the *T. gondii* strain ([@b0640]).

In addition to ADA inhibition, CD73-generated adenosine can contribute to the pathogenesis of cerebral toxoplasmosis. CD73-deficient mice are less susceptible to cystogenic *T. gondii* (ME-49) infection than are WT animals. CD73 expression increases in the brain throughout the infection. CD73^−/−^ animals showed a significant reduction in parasitic load during the chronic phase when compared to the WT group. Furthermore, CD73 induced tachyzoite-to-bradyzoite differentiation in glial cells, suggesting that adenosine generation by host cells contributes to cyst formation and infection persistence in the CNS ([@b0450]). These reports suggest a crucial role for purinergic signaling in cerebral toxoplasmosis. The P2X7 receptor participates in the activation of microbicidal mechanisms and parasite control, while adenosine generation favors the persistence of the parasite in the CNS.

Malaria is an infectious disease caused by parasites of the genus *Plasmodium*. This disease is transmitted by female *Anopheles* mosquitoes that inject sporozoites into the host, and infected patients can have moderate-to-severe malaria, characterized by anemia, fever, and, in some cases, cerebral manifestations ([@b0440]). *Plasmodium falciparum* is responsible for the most significant number of malaria cases worldwide. Cerebral malaria is a critical clinical complication of *P. falciparum* infection, characterized by neuroinflammation, seizures, unconsciousness, coma, and diffuse encephalopathy ([@b0440]).

Purinergic signaling is involved in malaria pathophysiology because *Plasmodium*-infected erythrocytes release large amounts of ATP, and the P2X7 receptor is critical for a beneficial Th1 immune response to this disease ([@b0010]; [@b0575]). In a murine model of cerebral malaria, the expression of purinergic receptors varied according to receptor subtype and brain region studied. P2X1 and P2Y~2~ expression increased in the olfactory bulb, prefrontal cortex, and hippocampus, while P2Y~12~ and P2Y~13~ expression increased in the cerebellum ([@b0460]). Nevertheless, further studies are required to determine the functional role of these receptors in cerebral malaria.

*Trypanosoma evansi* is a protozoan that causes neurological dysfunction in several mammals ([@b0295]). In humans, the first case of *T. evansi* infection was reported in India. The infected individual presented with sensory deficit, disorientation, and violent behavior ([@b0380]). In the context of purinergic signaling, [@b0520] detected increased ATP, ADP, and AMP hydrolysis in synaptosomes isolated from the cerebral cortex of *T. evansi*-infected rats 5 days post-infection, while ADA activity was reduced in these settings ([@b0165]). These results suggest an accumulation of adenosine in the cerebral cortex of infected rats; however, another study from the same group found increased ATP and ADP levels and decreased ADO concentrations in this brain region 5 days after *T. evansi* infection ([@b0170]). During the chronic phase, increased levels of adenosine were detected in the brain *T. evansi*-infected rats, possibly favoring neuroprotection and neuromodulatory mechanisms during the infection ([@b0170]).

2.5. Targeting purinergic signaling in neuroinfectious diseases {#s0035}
---------------------------------------------------------------

Given the important role of purinergic signaling in infectious diseases of the CNS, therapeutic approaches targeting this signaling would represent feasible strategies to treat these diseases and their associated neurological symptoms. Brain-penetrant purinergic receptor agonists and antagonists, as well as ectonucleotidases inhibitors, have been tested in preclinical or clinical studies, as detailed in recent reviews ([@b0015], [@b0030], [@b0220], [@b0590], [@b0710]). In this section, we discuss some examples of drugs that could modulate purinergic signaling in neuroinfections.

P2X7, P2X4, and P2X3 are the most relevant P2X receptors from a neuropharmacological perspective. The availability of brain-permeable P2X7 inhibitors is limited. BBG and A438079 are P2X7 antagonists that efficiently cross the blood--brain barrier. BBG is most commonly used in animal models of neurological diseases, while the use of A438079 is less attractive because of its unfavorable pharmacokinetic proprieties ([@b0590]). JNJ-554175446 and JNJ-55308942 are promising brain-penetrant P2X7 receptor antagonists that have been evaluated in clinical trials for treatment of neuropathologies ([@b0030]). P2X4 receptor inhibition has also been proposed to treat these diseases. However, most of the drugs described for this receptor are allosteric ligands with low potency and poor aqueous solubility (i.e., 5-BDBD and BX-430). The most exciting P2X4 antagonist to control pain by acting in glial cells is the NC-2600, which is currently in a phase II clinical trial ([@b0710]). Furthermore, A-317491, a selective and competitive antagonist for both homomeric P2X3 and heteromeric P2X2/P2X3 receptors, attenuates tactile allodynia and thermal hyperalgesia in a classic neuropathic pain model ([@b0365]).

P2Y receptor ligands have also been studied for neuroprotective purposes. P2Y~2~ and P2Y~4~ receptors may have complementary effects by activating microglial phagocytosis and pinocytosis of soluble amyloid β protein fragments in Alzheimer's disease ([@b0005]). Diquafosol (INS365), a P2Y~2~ agonist, has already been approved as a topical treatment for dry-eye disease ([@b0700]), and two additional agonists are in clinical trials (INS37217 and MRS2698) ([@b0710]). P2Y~1~ inhibition attenuates cognitive dysfunction after brain injury ([@b0290]). The activation of P2Y~1~ by the agonist ﻿MRS2365 boosts inflammatory responses and increases the infarct volume in a stroke model, while the antagonist MRS2179 show opposite protective effects after cerebral ischemia ([@b0260], [@b0400]). P2Y~6~ antagonist MRS2578 reduces inflammatory neurodegeneration, while the agonist MRS-2693 induces microglia activation and neuronal loss ([@b0505]). P2Y~12~ receptor is also an exciting target for neuroinflammatory diseases by control microglia migration and process extension. Initially developed to restrain platelet aggregation, P2Y~12~ antagonists are commercially available, including ticlopidine (Ticlid), clopidogrel (Plavix), ticagrelor (Brilinta), prasugrel (Effient), and ticagrelor (AR-C69931) ([@b0025], [@b0685]).

The P1 receptors are also therapeutic targets for CNS diseases. A~1~ and A~2A~ receptors are the central adenosine receptors expressed in the brain, and they usually have contrasting effects. The A~1~ receptor has neuroprotective activities, while A~2A~ receptor is considered a neurodegenerative receptor ([@b0630]). The development of A~1~ agonists and A~2A~ antagonists could then have beneficial effects on neurological disorders ([@b0125]). Although most adenosine receptor drugs are unable to cross the BBB, MMPD and ﻿MRS5474 can act as brain A~1~ agonists, and MRS5474 showed antidepressant properties ([@b0360]). Furthermore, A~2A~ antagonists such as istradefylline and SCH58261 can inhibit microglial activation and excitotoxicity ([@b0710]). Other adenosine receptor drugs in CNS diseases have been extensively reviewed in Effendi et al. ([@b0220]).

Finally, ectonucleotidase inhibitors could be used for modulating the extracellular availability of nucleotides and nucleosides and, consequently, the activation of purinergic receptors during brain infections. Sodium polyoxotungstate (POM-1) and ARL6715 are the primary NTPDase/CD39 inhibitors that have been used to increase ATP availability, whereas soluble apyrase has been used to scavenge ATP ([@b0015], [@b0035]) APCP (α, β-methyleneadenosine 5′-diphosphate monosodium salt) is the main inhibitor of CD73 limiting adenosine generation ([@b0035]). In addition to these drugs, CD39/CD73-neutralizing antibodies are also feasible therapeutic strategies for modulating purinergic signaling ([@b0015]).

3. Concluding remarks {#s0040}
=====================

The immune and nervous systems are actively integrated and they modulate several physiological and pathological mechanisms. An understanding of the integrated mechanisms of these two physiological systems is fundamental for the development of new therapeutic strategies for infectious diseases that affect the central nervous system.

Purinergic signaling is an evolutionarily well-conserved signaling pathway that modulates immune and neural responses, serving as a communication link between these two systems. In general, ATP-P2 receptor signaling has pro-inflammatory and deleterious effects, aggravating viral infections that affect the CNS, while adenosine appears to have anti-inflammatory and protective effects. In bacterial infections, ATP signaling appears to have beneficial effects on cells of the immune system, inducing infection control. However, in cerebral parenchymal cells, this signaling has deleterious effects, promoting neuroinflammation, excitotoxicity, and neurodegeneration. By contrast, the activation of P2 receptors, mainly the P2X7 receptor, appears to be crucial for control parasitic infections by inducing the activation of microbicidal mechanisms. Adenosine signaling in parasitic infections appears to favor the parasite persistence in the CNS, as in cerebral toxoplasmosis ([Fig. 1](#f0005){ref-type="fig"}). Taken together, the data suggest that deleterious or beneficial outcomes depend on the pathogen species and its virulence, as well as the particular component of purinergic signaling involved in the neuroinfectious disease.

An understanding of purinergic signaling in infectious diseases that affect the CNS may suggest new therapeutic strategies, for example, the administration of purinergic receptor agonists/antagonists and soluble apyrases that mimic the action of ectonucleotidases. Furthermore, the administration of CD39 neutralizing antibodies is an exciting alternative in cases where ATP signaling is important for infection control.
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